Edition:
United States

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

7.91USD
3:59pm EST
Change (% chg)

$-0.09 (-1.12%)
Prev Close
$8.00
Open
$8.11
Day's High
$8.11
Day's Low
$7.84
Volume
148,574
Avg. Vol
104,266
52-wk High
$10.25
52-wk Low
$6.03

Latest Key Developments (Source: Significant Developments)

Cytokinetics Q3 Loss Per Share $0.40
Thursday, 1 Nov 2018 04:00pm EDT 

Nov 1 (Reuters) - Cytokinetics Inc ::CYTOKINETICS, INC. REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.40.Q3 EARNINGS PER SHARE VIEW $-0.51 -- THOMSON REUTERS I/B/E/S.FORTITUDE-ALS ON TRACK TO COMPLETE ENROLLMENT BY YEAR END.METEORIC-HF ADVANCING TO TRIAL INITIATION.EXPECT THAT AMGEN WILL INITIATE A PHASE 1 PROGRAM FOR AMG 594 BEFORE END OF YEAR.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $210.3 MILLION AT SEPTEMBER 30, 2018.  Full Article

Cytokinetics Announces Progress Against Vision 2020
Wednesday, 3 Jan 2018 07:30am EST 

Jan 3 (Reuters) - Cytokinetics Inc ::CYTOKINETICS ANNOUNCES PROGRESS AGAINST VISION 2020.CYTOKINETICS INC - ‍RESULTS FROM FOUR CLINICAL TRIALS OF CK-2127107 EXPECTED IN 2018​.CYTOKINETICS INC - RESULTS FROM FOUR CLINICAL TRIALS OF CK-2127107 EXPECTED IN 2018.CYTOKINETICS INC - ‍ENROLLMENT OF PATIENTS IN GALACTIC-HF IS ON TRACK IN 2018​.  Full Article

Cytokinetics Inc announces negative results from VITALITY-ALS
Tuesday, 21 Nov 2017 07:30am EST 

Nov 21 (Reuters) - Cytokinetics Inc :Cytokinetics announces negative results from VITALITY-ALS.Phase 3 clinical trial of Tirasemtiv in patients with ALS did not meet primary or secondary endpoints​.No new safety or tolerability findings related to Tirasemtiv were identified in VITALITY-ALS​.Believe that limitations of Tirasemtiv may be addressed with co's next-generation fast skeletal muscle activator, CK-2127107​.Have decided to suspend development of Tirasemtiv​.Limitations of Tirasemtiv may be addressed with co's "next-generation fast" skeletal muscle activator, CK-2127107​.Believe CK-2127107 will be better tolerated, potentially more effective than Tirasemtiv for ALS & look forward to phase 2 results in 2018​.  Full Article

Cytokinetics enters into second amendment to certain loan and security agreement
Tuesday, 31 Oct 2017 04:32pm EDT 

Oct 31 (Reuters) - Cytokinetics Inc ::Cytokinetics - ‍on Oct 27, entered into second amendment to certain loan and security agreement dated as of October 19, 2015 .Cytokinetics - ‍original loan agreement, as amended by amendment, provides for secured growth capital term loans of up to $50.0 million​.  Full Article

Cytokinetics reports Q3 loss of ‍$0.60/shr​
Thursday, 26 Oct 2017 04:00pm EDT 

Oct 26 (Reuters) - Cytokinetics Inc :Cytokinetics, Inc. reports third quarter 2017 financial results.Q3 revenue $6.2 million versus I/B/E/S view $6.5 million.Cytokinetics Inc - qtrly loss per share ‍$0.60​.Cytokinetics Inc- ‍anticipates cash research and development expenses will be in range of $103 million to $107 million for 2017​.  Full Article